TP53 and non-small cell lung carcinoma: To assess if CRISPR/Cas9 gene editing can be utilized to recapitulate NSCLC in vivo, we compared the classic mouse model Trp53fl/fl:KRaslsl–G12D/wt (C57BL6/J background, KPGEMM) infected with an adeno-associated virus (AAV) encoding Cre recombinase with Rosa26Sor–CAG–Cas9–IRES–eGFP mice (C57BL6/J background) infected with an AAV encoding single guide RNA (sgRNA) to target Trp53 and mutate KRas to KRasG12 (KPCRISPR) (Figure 1B and Supplementary Movie 1).